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In mammalian cells, MCTs (monocarboxylate transporters)
require association with an ancillary protein to enable plasma
membrane expression of the active transporter. Basigin is the
preferred binding partner for MCT1, MCT3 and MCT4, and
embigin for MCT2. In rat and rabbit erythrocytes, MCT1
is associated with embigin and basigin respectively, but its
sensitivitytoinhibitionbyAR-C155858wasfoundtobeidentical.
Using RT (reverse transcription)–PCR, we have shown that
Xenopus laevis oocytes contain endogenous basigin, but not
embigin. Co-expression of exogenous embigin was without
effect on either the expression of MCT1 or its inhibition by
AR-C155858. In contrast, expression of active MCT2 at the
plasma membrane of oocytes was signiﬁcantly enhanced by
co-expression of exogenous embigin. This additional transport
activity was insensitive to inhibition by AR-C155858 unlike that
by MCT2 expressed with endogenous basigin that was potently
inhibited byAR-C155858.Chimaeras andC-terminal truncations
of MCT1 and MCT2 were also expressed in oocytes in the
presence and absence of exogenous embigin. L-Lactate Km values
for these constructs were determined and revealed that the TM
(transmembrane) domains of an MCT, most probably TM7–
TM12, but not the C-terminus, are the major determinants of
L-lactate afﬁnity, whereas the associated ancillary protein has
little or no effect. Inhibitor titrations of lactate transport by these
constructs indicated that embigin modulates MCT2 sensitivity
to AR-C155858 through interactions with both the intracellular
C-terminus and TMs 3 and 6 of MCT2. The C-terminus of MCT2
was found to be essential for its expression with endogenous
basigin.
Key words: basigin, embigin, erythrocyte, lactate transport,
monocarboxylate transporter 1 (MCT1), monocarboxylate
transporter 2 (MCT2).
INTRODUCTION
The transport of L-lactate across the plasma membrane
of mammalian cells is catalysed by proton-linked MCTs
(monocarboxylatetransporters)ofwhichfourisoformshavebeen
characterized: MCT1, MCT2, MCT3 and MCT4 [1–5]. These
transportersareencodedbyseparategenesandbelongtotheMCT
family [SLC16 (solute carrier 16)] that contains 14 members in
humansandmice[6].MCT1iswidely expressedandisimportant
fortheuptakeoflacticacidbyheartandredskeletalmuscle,where
it acts as a major respiratory fuel, and for gluconeogenesis in the
liverandkidneyofsomespecies[7–11].MCT2isahigher-afﬁnity
transporter [2] and may facilitate the uptake of lactic acid for
gluconeogenesis in the liver and kidney where it is the dominant
MCT isoform in some, but not all, species [6,9,12]. MCT2 is
also expressed in neurons, especially at the postsynaptic density,
where it may facilitate the uptake of lactic acid, produced by
glycolysisinastrocytes,foroxidationasarespiratoryfuel[13,14].
The expression of MCT3 is limited to the basal membrane of the
retinal pigment epithelium and choroid plexus epithelia [15,16],
whereas MCT4 is primarily expressed in highly glycolytic cells,
such as white muscle ﬁbres, where it is used to facilitate lactic
acid efﬂux from the tissue [17,18], and is up-regulated in other
cells under hypoxic conditions [19].
All members of the MCT family are predicted to have 12 TM
(transmembrane) α-helices with a large loop between TMs 6 and
7 that faces the intracellular side of the membrane as do the
C- and N-termini. For most MCT isoforms, the N-terminus is
relatively short, whereas the C-terminus and TM6/7 loop are
quite long and show little sequence identity between isoforms
[6,11]. For MCT1, the proposed structure has been conﬁrmed
by proteolytic cleavage and labelling studies, as well as by
molecular modelling [20–23]. An ancillary protein, either basigin
orembigin,isrequiredforMCT1–MCT4tobeproperlyexpressed
attheplasmamembrane[21–24].Embiginandbasiginaresingle-
TM glycoproteins with two or three extracellular Ig domains
[25–28], and the continued interaction between the MCT and
its ancillary protein is essential to maintain transporter activity
[21,22]. Basigin is the normal binding partner for MCT1, MCT3
and MCT4 [22,29–34], although MCT1 may be expressed with
embigin in some tissues such as rat erythrocytes [24]. In contrast,
MCT2 prefers embigin as its binding partner [22].
In order to elucidate the importance of each MCT isoform
in particular metabolic pathways and disease states, it would
be highly desirable to develop isoform-speciﬁc inhibitors. A
new class of speciﬁc and extremely high-afﬁnity inhibitors of
MCT1 have been discovered by AstraZeneca [35–37]. We have
conﬁrmed the ability of one of these inhibitors, AR-C155858,
to inhibit MCT1 in rat erythrocytes with a Ki value of approx.
2 nM and demonstrated similar high-afﬁnity inhibition of both
M C T 1a n dM C T 2w h e nt h e ya r ee x p r e s s e di nXenopus laevis
oocytes. In contrast, MCT4 was not inhibited, and by studying
Abbreviations used: BCECF, 2 ,7 -bis-(2-carboxyethyl)-5(6)-carboxyﬂuorescein; CFP, cyan ﬂuorescent protein; EST, expressed sequance tag; FRET,
ﬂuorescence resonance energy transfer; HA, haemagglutinin; MCT, monocarboxylate transporter; MCT1trn, MCT1 without C-terminus; MCT1/2c, MCT1
with MCT2 C-terminus; MCT2trn, MCT2 without C-terminus; MCT2/1c, MCT2 with MCT1 C-terminus; pCMBS, p-chloromercuribenzene sulfonate; RT,
reverse transcription; TM, transmembrane; WT, wild-type; YFP, yellow ﬂuorescent protein.
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MCT1/MCT4 chimaeric transporters, we were able to locate
the inhibitor binding site to TMs 7–10 of the C-terminal half
of MCT1 [38]. In studies directed towards establishing the
relationship between the structure and function of MCT2, we
foundthat co-expressing MCT2with embigin inX.laevis oocytes
signiﬁcantly increased plasma membrane expression and activity
of the transporter. However, when we investigated the inhibition
of MCT2 activity by AR-C155858 under these conditions, we
found a major reduction in inhibitor sensitivity. In the present
paper, we report the results of these studies and provide evidence
for an interaction of embigin with both the C-terminus and TM3
and TM6 of MCT2, but not MCT1, that plays an important role
in mediating this reduced inhibitor sensitivity.
EXPERIMENTAL
Materials
All reagents were obtained from Sigma unless stated otherwise,
and most antibodies were obtained from the sources cited in
[38]. Rabbit polyclonal antibodies against the C-terminus of rat
embiginwereraisedin-houseasdescribedpreviously[22],andthe
anti-HA(haemagglutinin)antibodywaspurchasedfromCovance.
Restriction enzymes were obtained from Roche Applied Science.
Rat and rabbit blood were purchased from Harlan SeraLabs.
X. laevis toads were obtained from Xenopus Express and oocytes
were harvested as described previously [21]. L-[
14C]Lactate was
obtained from GE Healthcare. AR-C155858 was obtained from
AstraZeneca and made up as a 10 mM stock in DMSO.
Detection of basigin and embigin in Xenopus oocytes by RT
(reverse transcription)–PCR
A BLAST search of the EST (expressed sequence tag) database
with the protein sequence for rat basigin and embigin identiﬁed a
full-length mRNA sequence for X. laevis basigin (BC099064.1)
and a partial mRNA sequence (853 bp) that was highly
homologous with embigin (EB645817). Whereas the former
was common in the EST database, the embigin sequence
gave only three hits (thymus cDNA library). These sequences
were used to design primers (see Supplementary Table S1
at http://www.BiochemJ.org/bj/431/bj4310217add.htm) for PCR
detection of embigin and basigin in X. laevis oocytes using
Xenopus thymus tissue as a positive control. RNA was extracted
from the oocytes and thymus using TRIzol® reagent (Invitrogen)
following the manufacturer’s protocol. cDNA was synthesized
with Expand Reverse Transcriptase (Roche) and used in PCRs.
Thermocycling was performed using the following parameters:
1m i na t9 5◦C, 1 min at 55◦C and 1 min at 72◦C for 5 cycles,
a n d1 m i na t9 5 ◦C, 1 min at 50◦C and 1 min at 72◦Cf o r
30 cycles. PCR products were analysed by agarose gel electro-
phoresis.
Generation of MCT chimaeras and truncations of rat MCT1 and
MCT2
Chimaeras of MCT1 and MCT2 were created in which the N- and
C-terminal halves either side of the TM6/7 loop (MCT2/1 and
MCT1/2) or just the C-terminal tails (MCT1/2c and MCT2/1c)
wereswapped.Therationaleandmethodologyusedwasthesame
as that described previously [38]. The MCT1/2 and MCT2/1
loop chimaeras were produced based upon a stretch of nucleotide
sequence similarity near the end of the TM6/7 large intracellular
loop consisting of residues (P/K)(K/R)(G/L)(E/S)K(L/V)S
(MCT1/MCT2). Similarly the MCT1/2c and MCT2/1c
C-terminal chimaeras were based on a conserved YRL (Tyr-
Arg-Leu) sequence one residue downstream of the end of TM12
for both MCT1 and MCT2. Sequences for all primers used
are given in Supplementary Table S1 and were designed to be
between 15 and 30 bases in length. The C-terminal truncation
of MCT1 (MCT1trn) was produced as described previously [38].
For C-terminal truncation of MCT2 (MCT2trn), PCR was used
to produce MCT2 lacking the sequence C-terminal of the end
of TM12, just as was performed when making the MCT2/1c
chimaera, but the product was ligated into the pGEM-T Easy
vector system (Promega). From here, it was extracted by EcoRI
digestion and ligated into EcoRI-linearized oocyte pGHJ vector
with a stop codon within the plasmid sequence downstream of
MCT2trn. Since the anti-MCT2 antibodies were raised against
the C-terminus, in order to monitor plasma membrane expression
ofMCT2trn,anHAtag(ashortpeptidesequence,YPYDVPDYA)
wasaddedtotheN-terminusofMCT2.Thiswasperformedbyin-
sertionoftheMCT2trnconstructintoalinearizedpcDNA3vector
(Invitrogen)previouslymodiﬁedbyDrHarryMellor(Department
of Biochemistry, University of Bristol) to include the HA tag
upstream of the inserted DNA (HA-pcDNA3), while maintaining
the reading frame between the HA tag and MCT sequence.
Subsequently,theHA–MCT2trnconstructwasextractedfromthe
pcDNA3vectorusingPCRwiththeprimersgiveninSupplement-
ary Table S1. These contained XbaI restriction enzyme sites both
upstream and downstream of the HA–MCT2trn cDNA, enabling
insertion of the HA-tagged construct into the appropriately lin-
earized pGHJ vector. Conﬁrmation that all of the desired changes
hadbeencorrectlyengineeredwasprovidedbysequencing(DNA
Sequencing & Services, University of Dundee, Dundee, U.K.).
Measurement of MCT1 activity in erythrocytes
L-Lactate transport into rat and rabbit erythrocytes was measured
by monitoring the change in extracellular pH with a pH-sensitive
electrode as described previously [22,38]. The erythrocytes (5%
haematocrit) were pre-incubated for 1 h at room temperature
(22◦C)withorwithoutAR-C155858attherequiredconcentration
beforeassayingtransportof L-lactate(10 mM)at6◦C.Initialrates
of transport were calculated by ﬁrst-order regression analysis of
the time course of pH change and converted into nmol of H
+/min
by determining the pH change induced by small additions of
standardized NaOH.
Measurement of MCT transport activity in Xenopus oocytes
cRNA was prepared and injected into X. laevis oocytes as
described previously [21,38]. For all assays, 10 ng of MCT
cRNA + −10 ng of rat embigin cRNA in 9.2 nl of water were
injected, with controls receiving just water. MCT and embigin
expression at the plasma membrane of oocytes was conﬁrmed
by immunoﬂuorescence microscopy as described previously
[21,38]. MCT kinetic assays were performed by monitoring
intracellular pH with H
+-sensitive dye BCECF [2
 ,7
 -bis-(2-
carboxyethyl)-5(6)-carboxyﬂuorescein] or by determining the
uptake of L-[
14C]lactate (7.4 MBq/ml) [5,21,23,38]. The uptake
buffer contained 75 mM NaCl, 2 mM KCl, 0.82 mM MgCl2,
1m M C a C l 2 and 20 mM Tris/Hepes (pH 7.4). AR-C155858
inhibitor titrations were performed at pH 6 with oocytes pre-
incubated for 45 min in a different uptake buffer (75 mM NaCl,
2mMKCl,0.82mMMgCl 2,1 mMCaCl2 and20 mMMes,pH 6)
containing the required concentration of AR-C155858 prior to
measuring the uptake of L-[
14C]lactate (0.5 mM) as described
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previously [38]. Unless stated otherwise, uptake was determined
over 2.5 min for all MCT constructs except for MCT2trn with
or without embigin and MCT2/1 with or without embigin, where
5 and 10 min were used respectively. We determined that these
conditions represented the longest period over which uptake was
linear with time (results not shown).
RESULTS
Embigin enhances MCT2 expression in Xenopus oocytes
We have shown previously that MCT2 usually associates with
embigin rather than basigin [22]. If Xenopus oocytes express
endogenous basigin, but not embigin, this might explain the poor
expression of exogenous MCT2 relative to MCT1 [38]. In order
to determine whether or not this was the case, we performed
RT–PCR analysis of mRNA extracted from Xenopus oocytes
using primers designed against Xenopus basigin and embigin
as described in the Experimental section. Results are reported
in Figure 1(A). As anticipated, a strong signal was found for
basigin,butnotforembigin.Asapositivecontrol,wewereableto
detect embigin using mRNA from Xenopus thymus in agreement
with the presence of embigin in a Xenopus thymus cDNA library
(EST database accession number EB645817). Since we do not
have suitable antibodies to detect endogenous Xenopus embigin
or basigin, we were unable to conﬁrm these results at the protein
level. However, using Western blot analysis of a crude membrane
fraction (Figure 1B) and confocal microscopy of sections of
Xenopus oocytes (Figure 1C), we were able to conﬁrm that, when
oocytes were co-injected with cRNA for rat embigin and MCT2,
theplasmamembraneexpressionofMCT2wasincreasedrelative
totheMCT2expressedintheabsenceofembigin.Coincidentwith
this, the co-expression of embigin reduced the amount of MCT2
located in a compartment beneath the plasma membrane in the
absenceofembigin(Figure1C)andincreasedtherateof L-lactate
transportintotheoocytes(Figure2).Incontrast,embiginfailedto
enhance the plasma membrane expression of MCT1 (Figures 1B
and 1C) and produced no increase in the rate of lactate transport
(Figure2).ThemodestexpressionofMCT2intheabsenceofem-
bigin is likely to reﬂect its association with endogenous Xenopus
basiginoracurrentlyunidentiﬁedancillaryprotein.Weconﬁrmed
this by demonstrating that when this endogenous basigin was
knocked down by microinjecting an antisense cDNA against
basigin, expression of MCT2 was greatly reduced (Figure 1D).
This was associated with rates of lactate transport a little higher
than in non-injected controls. Scrambled antisense cDNA was
without effect on either MCT2 expression or lactate transport.
Embigin reduced the sensitivity of MCT2, but not MCT1,
to inhibition by AR-C155858
In Figure 2, we show that co-expression of embigin with MCT1
had no effect on the high sensitivity of this isoform to inhibition
by AR-C155858. However, the situation with MCT2 was more
complex. In the absence of embigin, the ﬁrst addition of the
inhibitor (10 nM) reduced the rate of transport by approx.
20 pmol/min per oocyte, which represented a 70% inhibition of
transport.Withfurtherinhibitoradditions,therewasaprogressive
inhibition that reached nearly 100% at 100 nM AR-C155858 as
describedpreviously[38].Inthepresenceofembigin,theabsolute
reduction in transport rate by 10 nM AR-C155858 was again
approx. 20 pmol/min per oocyte, but further additions of AR-
C155858 gave little additional inhibition. Indeed, the difference
between the rate of lactate uptake in the presence and absence
Figure 1 Importance of embigin for MCT2 expression in oocytes
(A) Expression of endogenous basigin (Bas) and embigin (Emb) in X. laevis oocytes and
thymus determined by RT–PCR. Sizes are indicated in bp. (B) Membrane preparations of
oocytes expressing MCT1 or MCT2 in the presence or absence of embigin were subject to
SDS/PAGE and Western blotting with the anti-MCT1 or the anti-MCT2 antibody as indicated.
Sizes are indicated in kDa. (C) Immunoﬂuorescence confocal microscopy on sections of the
oocytes using the appropriate antibody against rat MCT1 or MCT2 with or without embigin
(Emb). For MCT2 in the absence of embigin, arrows show weak plasma membrane (PM) and
stronger intracellular (IC) expression. (D) L-[14C]Lactate uptake (mean+S.E.M., n=20–30)
for water-injected oocytes and those expressing MCT2 in the presence or absence of antisense
oligonucleotide against endogenous basigin or a scrambled antisense (AS) oligonucleotide. A
Western blot of a crude membrane preparation is shown to conﬁrm knockdown of MCT2.
of embigin remained almost constant at approx. 40 pmol/min
per oocyte concentrations as the AR-C155858 concentration was
increased from 10 nM to 100 nM. Thus approx. 50% of transport
mediated by MCT2 co-expressed with embigin appears to be
resistant to inhibition by AR-C155858. It would seem probable
that this inhibitor-insensitive transport represents the activity of
MCT2 that is associated with embigin, whereas the remaining
50% that is inhibitor-sensitive represents transport mediated by
MCT2 associated with endogenous basigin. No such inhibitor-
insensitivetransportwasobservedwhenMCT1wasco-expressed
with embigin.
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Figure 2 The sensitivity of MCT2 to inhibition by AR-C155858 is decreased
by co-expression of embigin
Inhibition of L-lactate transport activity at pH6 by increasing concentrations of AR-C155858
was determined using 0.5mM L-[14C]lactate (pH6). Results are means+ −S.E.M. for 27–107
separate oocytes at each inhibitor concentration.
Figure 3 Sensitivity to inhibition by AR-C155858 of MCT1 associated with
basigin or embigin in rabbit and rat erythrocytes respectively
The rate of transport of 10mM L-lactate (pH7) into rabbit or rat blood at 5% haematocrit
was monitored by extracellular pH following 1h of pre-incubation with the concentration of
AR-C155858. The inset shows the superimposed data for both species with rates expressed as
percentages of control (no inhibitor). Linear regression was used to calculate the plot.
Although it is quite possible that the MCT1 continues to utilize
endogenous basigin rather than embigin under these conditions,
we have shown previously that in rat erythrocytes, where MCT1
is naturally expressed in association with embigin, AR-C155858
still inhibits lactate transport potently with a Ki value of 2.3 nM
[38]. However, to conﬁrm that MCT1 sensitivity to AR-C155858
is unaffected by its choice of ancillary protein, we compared
inhibitor titrations of lactate transport into rabbit erythrocytes,
where MCT1 is naturally expressed in association with basigin
[22], with those of rat erythrocytes, where embigin acts as the
ancillary protein. The results are shown in Figure 3. As described
previously for rat erythrocytes [38], the potency of inhibition is
such that a linear relationship between [AR-C155858] and rate
of transport is observed for both species. The extrapolation to
zero rate gives an approximate estimate of the number of binding
sites for the inhibitor which is similar for both rat and rabbit
erythrocytes despite the 2-fold higher absolute rate of transport
seen in the rabbit erythrocytes at the same pH. When rates of
transport are expressed as a percentage of control (zero inhibitor)
the two plots superimpose (inset), also implying that there are a
similar number of binding sites with the same afﬁnity for AR-
C155858 in both species. Thus the turnover number for MCT1
in rabbit erythrocytes must be approx. 2-fold higher than for rat
erythrocytes under these conditions. Our ﬁndings do not allow us
to determine with certainty whether this reﬂects an effect of the
ancillary protein on the kcat of MCT1 or whether it is a property
of the MCT itself.
Using MCT1/MCT2 chimaeras to investigate how embigin
co-expression desensitizes MCT2 to inhibition by AR-C155858
Since potent inhibition of MCT1 by AR-C155858 is observed
whether MCT1 is associated with embigin or basigin, we sought
to establish what regions of MCT2 are responsible for the
desensitizing effect of embigin. We have previously created
chimaericMCTsutilizingdifferentsegmentsofMCT1andMCT4
inordertoidentifytheregionofMCT1thatislikelytobethebind-
ingsiteforAR-C155858[38].Theseresultsidentiﬁedthebinding
sitetobeintheC-terminalhalfofthemolecule.Thusweadopteda
similar approach with MCT1/MCT2 chimaeras. We successfully
created a chimaera in which the N-terminal half of MCT2 (up
to the end of the intracellular loop between TMs 6 and 7) was
combined with the C-terminal half of MCT1. This chimaera
(MCT2/1) was strongly expressed at the plasma membrane of
the oocyte (Figure 4A) and gave kinetics of L-lactate transport,
determinedwiththeBCECFmethod,indistinguishablefromthose
forMCT1(Table1).Co-expressionofembiginhadnoeffectonthe
Km for L-lactate (Table 1), neither did it have a profound effect on
eitherthelevelofexpressionattheplasmamembrane(Figure4A)
or the Vmax of transport (Figure 4B). Inhibition of MCT2/1 in the
absence of embigin was similar to that of MCT1 (Figure 4B),
althoughwhenco-expressedwithembigin,thechimaeraappeared
slightlylesssensitivetotheinhibitor.However,ifassociationwith
embiginratherthanbasigindecreasesthekcat ofMCT2/1,thenthis
difference may merely reﬂect a greater expression of a less active
transporter rather than a decrease in inhibitor binding afﬁnity.
We were also able to express the equivalent MCT1/2 chimaera
at the plasma membrane of oocytes independently of embigin
(Figure 4), but these oocytes showed no increase in the rates of
L-lactatetransport,suggestingthischimaerawasinactiveforsome
reason.
We next created chimaeras in which just the C-terminal
tail was swapped between MCT1 and MCT2 (MCT1/2c and
MCT2/1c) or truncated MCT1 and MCT2 without the C-terminal
tail (MCT1trn and MCT2trn). Figure 5 shows that all of these
constructs facilitated lactate transport whether or not embigin
was co-expressed, with the exception of MCT2trn whose activity
requiredembiginco-expression.Asmightbepredicted,MCT1/2c
and MCT1trn exhibited similar rates of transport to that of
MCT1 with no stimulation of transport activity (Figure 5A)
or expression (Figure 5B and Supplementary Figure S1 at
http://www.BiochemJ.org/bj/431/bj4310217add.htm) when co-
expressed with embigin. More surprising was that the MCT2/1c
chimaera gave signiﬁcantly higher rates of lactate transport than
MCT2 itself with a less pronounced effect of co-expressed
embigin. However, when the C-terminal tail of MCT2 was totally
removed (MCT2trn), little, if any, transport was observed in
the absence of co-expressed embigin, whereas co-expression
with embigin bought about rates approx. 60% of full-length
MCT2 plus embigin. Interestingly, the absolute increase in rate
of transport by MCT2trn induced by embigin was similar to that
observed for full-length MCT2. Expression data were consistent
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Table 1 Summary of the L-lactate Km values and sensitivity to inhibition by AR-C155858 of MCT chimaeras expressed in the presence and absence of
exogenous embigin
The Km values reported were derived either by monitoring changes in intracellular pH with BCECF or using L-[14C]lactate uptake (asterisk) as described in the Experimental section. The majority of
the kinetic data was obtained using the BCECF technique which was preferred over the radioactive technique since it allowed a single egg to be used for a complete Km estimation, reducing errors
associated with the various levels of expression. However, this technique could not be used for MCT2 and chimaeras that were poorly expressed and have low Km values because the pH changes
associated with uptake were too small to detect accurately with BCECF. In these cases, we needed to use the radioactive technique as we have done previously [2]. Results are means+ −S.E.M.
derived from the ﬁt of the mean data to the Michaelis–Menten equation by non-linear least-squares analysis. For L-[14C]lactate uptake, L-lactate concentrations used were 0.2, 0.5, 1, 2 and 5 mM,
whereas for BCECFmeasurements, the concentrationswere2.5, 5, 10,20 and 50mM. The n values given in parenthesesrepresent the number of separate eggsused at each substrateconcentration.
The expression at the plasma membrane is a qualitative indicator only, with +++ for good expression (as for MCT1 with or without embigin), ++ for modest expression (as for MCT2/1c without
embigin), + for poor expression (as for MCT2 without embigin) and − for no expression (as for MCT2trn without embigin). The transporter activity represents the activity in the absence of inhibitor
as monitored by L-[14C]lactate (0.5mM, pH6) uptake with results as means+ −S.E.M. (as for Figure 5). Initial sensitivity to AR-C155858 describes the decrease in rate between control and 10nM
AR-C155858 as a percentage of the control rate, whereas the inhibitor-insensitive component is the rate remaining at 100nM AR-C155858 as a percentage of the control rate+ −S.E.M. Inhibitor data
are taken from Figures 2, 4 and 6 and are expressed with or without (in parentheses) correction for rates of uptake in water-injected oocytes. n/a, not applicable.
Embigin Expression at Activity Initial sensitivity Inhibitor-insensitive
MCT chimaera co-expressed plasma membrane (pmol/min per oocyte) Lactate Km (mM) to AR-C155858 (%) component (%)
MCT1 No +++ 85+ −6.4 (30) 4.4+ −1.5 (4) 28+ −3( 2 6+ −3) 1.9+ −0.6 (8+ −0.6)
MCT1 Yes +++ 119+ −7.8 (30) 6.1+ −1.7 (4) 34+ −5( 3 2+ −5) 7.4+ −1.3 (12+ −1)
MCT2 No + 32+ −3 (30) 1.0+ −0.2 (8)* 51+ −7( 4 2+ −6) 12+ −2( 2 5+ −2)
MCT2 Yes +++ 83+ −3.3 (106) 2.3+ −0.3 (8)* 31+ −4( 2 8+ −4) 43+ −3( 4 7+ −3)
MCT1/2 No +++ 1.8+ −0.3 (10) n/a n/a n/a
MCT1/2 Yes +++ 2.3+ −0.3 (10) n/a n/a n/a
MCT1/2c No +++ 143+ −2.7 (20) 4.4+ −1.4 (6) 21+ −2( 2 0+ −2) 6+ −0.4 (10+ −0.4)
MCT1/2c Yes +++ 127+ −3.7 (20) 4.3+ −1.2 (6) 6+ −6( 6+ −6) 44+ −4( 4 6+ −4)
MCT1trn No +++ 149+ −10.2 (20) 4.5+ −2.1 (7) 25+ −7( 2 4+ −7) 10+ −2( 1 3+ −1)
MCT1trn Yes +++ 139+ −5.4 (20) 4.5+ −1.0 (5) 27+ −5( 2 6+ −5) 12+ −1( 1 5+ −1)
MCT2/1 No +++ 40+ −2.2 (10) 5.04+ −0.60 (4) 40+ −5( 3 4+ −4) 0+ −3( 8+ −2)
MCT2/1 Yes +++ 54+ −4.4 (10) 4.70+ −0.96 (4) 34+ −13 (30+ −11) 20+ −4( 2 8+ −4)
MCT2/1c No ++ 74+ −6.1 (29) 2.4+ −2.2 (4) 33+ −6( 3 0+ −6) 21+ −2( 2 6+ −2)
MCT2/1c Yes +++ 103+ −7 (28) 1.5+ −0.5 (7) 10+ −8( 9+ −8) 73+ −6( 7 4+ −6)
MCT2trn No − 2.4+ −1.3 (15) n/a n/a n/a
MCT2trn Yes + 44+ −2.7 (28) 1.4+ −0.2 (8)* 46+ −3( 3 9+ −2) 37+ −3( 4 4+ −2)
with these transport data. Thus MCT2trn showed no detectable
expression at the oocyte plasma membrane unless co-expressed
with embigin (Figure 5B), whereas full-length MCT2 showed a
small expression at the plasma membrane that was enhanced by
embigin as described above (Figure 1C). It should be noted that,
in order to detect MCT2trn expression, we attached an HA tag
to the N-terminus of MCT2 as described in the Experimental
section and used anti-HA antibodies. This was necessary because
our own anti-MCT2 antibody was raised against the C-terminus
of MCT2 [9], which is not present in MCT2trn. The activity of
all other constructs also correlated with their plasma membrane
expression (see Supplementary Figure S1).
Having established the expression of the different C-terminal
constructsinthepresenceandabsenceofembigin,weinvestigated
their sensitivity to inhibition by AR-C155858. Figure 6(A) shows
that MCT1trn and MCT1/2c exhibit potent inhibition by AR-
C155858,similartothatobservedforMCT1itself(Figure2).Co-
expressionofembigindidnotaffectthesensitivityoftheMCT1trn
to AR-C155858, consistent with its effects on full-length MCT1
(Figure 2). However, the MCT1/2c chimaera showed an altered
sensitivity to inhibition by AR-C155858 when co-expressed with
embigin (Figure 6A), similar to that observed for the MCT2/1
chimaera (Figure 4). These results imply that the presence of
the C-terminus of MCT2 led to expression of some of the
chimaera with embigin rather than endogenous basigin and that
thisinteractioncausedtheobservedreductioninsensitivitytoAR-
C155858. Desensitization was characterized by a shallower slope
of the inhibition plot compared with that for MCT1 and is distinct
from the effect of embigin on the AR-C155858 inhibition proﬁle
of MCT2. In the case of MCT2, the initial proﬁle of the inhibition
plot was similar to that for MCT1 at low inhibitor concentrations,
but then reached a plateau phase in which little additional
inhibitionoccurred(Figure2).Theshallowslopeoftheinhibition
proﬁle of MCT1/2c in the presence of embigin could be the result
of an interaction between the C-terminus of MCT2 with the
C-terminus of embigin. However, an alternative explanation
would be that MCT1/2c co-expressed with embigin showed
a greater expression, but lower kcat than when expressed with
endogenous basigin. This would give the same rate of transport
despite greater transporter expression, and thus a shallower
inhibitor titration as observed.
Help in discriminating between these two possibilities was
sought by studying a chimaera in which the C-terminus of
MCT2 was replaced with the MCT1 C-terminus (MCT2/1c).
This chimaera was active in the absence of co-expressed embigin
and was very sensitive to AR-C155858 as predicted, but with a
smallinhibitor-insensitivecomponentsimilartothatseenforfull-
length MCT2. However, the presence of the MCT1 C-terminus
appeared to enhance association with endogenous basigin since
the stimulation of transport seen by co-expression with embigin
was less for MCT2/1c than MCT2 (Figure 5A). Nevertheless,
when MCT2/1c was co-expressed with embigin the inhibitor-
insensitive component of transport was greater, implying that,
when associated with embigin rather than endogenous basigin,
MCT2/1c becomes inhibitor-insensitive. Consistent with this, the
majority of transport mediated by the C-terminally truncated
MCT2(MCT2trn)co-expressedwithembiginwasalsoinsensitive
to inhibition by AR-C155858.
DISCUSSION
The present study involved the use of a variety of MCT1/MCT2
chimaeras expressed in oocytes in the presence and absence
of embigin. To aid interpretation of the data, Table 1 provides
L-lactate Km values for all of the chimaeras and truncated MCTs
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Figure 4 The sensitivity of MCT1/2 and MCT2/1 chimaeras to inhibition by
AR-C155858
(A)ImmunoﬂuorescenceconfocalmicroscopydatawithappropriateC-terminalantibodies(Ab)
of sections of oocytes expressing MCT1/2 or MCT2/1 with or without exogenous embigin. (B)
Inhibition of lactate transport activity by increasing concentrations of AR-C155858 determined
using 0.5mM L-[14C]lactate (pH6) over 10min. Results are means+ −S.E.M. for ten separate
oocytes at each inhibitor concentration.
when expressed in the presence or absence of exogenous embigin
aswellassummarizingtheeffectsofembiginonMCTexpression
and inhibitor sensitivity. Figure 7 is a schematic diagram that
provides a tentative explanation of our data. Swapping or
truncation of the C-terminal tails had no effect on the L-lactate
Km values, but the MCT2/1 chimaera had a Km value more
similar to that of MCT1 (4–5 mM) than that of MCT2 (1–2 mM).
This is consistent with previous work that has implicated the
C-terminal half of MCT1 and MCT4 in their substrate afﬁnity
[7,21,23,39,40]. The presence or absence of exogenous embigin
had no signiﬁcant effect on Km values, suggesting that the kinetic
properties of an MCT are not greatly inﬂuenced by the ancillary
protein with which it is associated.
MCT2 requires embigin for optimal expression in Xenopus oocytes
We have shown previously that MCT2 is active when expressed
in Xenopus oocytes [4], but that rates of lactate transport are
substantially lower than for either MCT1 or MCT4 [38]. In
mammalian cells, we have shown that MCT2 preferentially
associates with embigin and that co-expression of embigin
rather than basigin with MCT2 is required to obtain plasma
membrane expression of MCT2 [22]. In the present study, we
havedemonstratedthatco-expressionofembiginwithMCT2also
enhances the plasma membrane expression and activity of MCT2
in Xenopus oocytes which contain endogenous basigin, but not
embigin(Figures1and2).TheexpressionofMCT2intheabsence
Figure 5 The C-terminus of MCT2 plays a role in its association with
endogenous basigin, but not co-expressed embigin
(A) Rates of L-[14C]lactate (0.5 mM) uptake into oocytes expressing the MCT or MCT chimaera
indicated, in the presence of absence of co-expressed embigin. Uptake was assayed at a time
where uptake is linear with time: 2.5 min for all except 5min for MCT1/2 and MCT2trn, and
10min for MCT2/1. Results are means+ −S.E.M. for the number of separate oocytes shown in
Table 1. (B) Immunoﬂuorescence microscopy data of the oocytes using C-terminal antibodies
against MCT2 or, in the case of the MCT2trn construct, against the HA tag inserted at the
N-terminus. Emb, embigin.
of embigin is assumed to reﬂect an association with endogenous
Xenopus basigin, since knockdown of this basigin using antisense
cDNA greatly reduced MCT2 expression and the associated
lactate transport (Figure 1D). It would appear that the C-terminal
tailofMCT2mustenablethisinteractionwithendogenousbasigin
because its removal prevented plasma membrane expression of
MCT2 unless embigin was co-expressed. In contrast, MCT1
without its C-terminal tail (MCT1trn) was expressed to an extent
similar to both full-length MCT1 and the MCT1/2c construct,
andembiginwaswithouteffectontheirexpression.TheMCT2/1c
constructwasalsoexpressedintheabsenceofembigin,but,inthis
case, expression was enhanced when embigin was co-expressed
(Figure 5A). However, the stimulation of transport seen by co-
expression with embigin was less for MCT2/1c than MCT2,
implying that the presence of the MCT1 C-terminus on MCT2
enhanced its association with endogenous basigin relative to full-
length MCT2.
Taken together, these data suggest that the interaction of MCT2
with its ancillary protein involves two components: the primary
association of the TM domain of the ancillary protein with
TMs 3 and 6 of MCT2 as proposed previously [21,22,31] and
a secondary interaction between the C-terminal tail of MCT2
and the C-terminal tail of the ancillary protein. When embigin is
theancillaryprotein,theinteractionwithTMs3and6issufﬁcient
to allow some expression, but this is enhanced by addition of
the C-terminal tail of either MCT1 or MCT2 to allow additional
interactionswiththeC-terminusofexogenousembigin.However,
the interaction of TMs 3 and 6 of MCT2 with endogenous basigin
may be relatively weak compared with that of embigin and thus,
in the absence of embigin, the C-terminal tail of either MCT2
or MCT1 is required to enhance the interaction with endogenous
basigin sufﬁciently to allow the plasma membrane expression of
the two proteins. The C-terminal tail of MCT1 is more effective
than that of MCT2 in this regard (Figure 5A) and it may be
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Figure 6 The sensitivity to inhibition by AR-C155858 of MCT1/MCT2
C-terminal chimaeras and truncations in the presence and absence of
co-expressed embigin
Inhibition of lactate-transport activity by increasing concentrations of AR-C155858 was
determined at pH6 using 0.5 mM L-[14C]lactate. Results are means+ −S.E.M. of 10–20 (A)o r
16–30(B)separateoocytesforeachinhibitorconcentration.Slightvariationsinthecontrolrates
fromthosereportedinFigure5aretypicalofthoseseenbetweendifferentbatchesofoocytesand
cRNApreparations.Immunoﬂuorescenceconfocalmicroscopyofoocytesectionsarepresented
in Supplementary Figure S1 at http://www.BiochemJ.org/bj/431/bj4310217add.htm to conﬁrm
plasma membrane expression of the different constructs. emb, embigin.
signiﬁcant that the amino acid sequences of these C-terminal tails
show little sequence conservation. Such an interaction between
the C-terminal tail of MCT1 and MCT2 with their ancillary
protein is consistent with previous data from this laboratory using
FRET (ﬂuorescence resonance energy transfer) between either
MCT1 or MCT2 tagged at the C-terminus with YFP (yellow
ﬂuorescent protein) and basigin or embigin tagged at their C-
terminuswithCFP(cyanﬂuorescentprotein).FRETwasobserved
when MCT1–CFP was co-expressed with basigin–YFP [31]
andwhenMCT2–YFPwasco-expressedwithembigin–CFP[22].
Embigin decreases the afﬁnity of MCT2, but not MCT1, for
AR-C155858
Although our data do not allow determination of absolute Ki
values for AR-C155858, Figures 2 and 3 show that, when
associated with embigin, the inhibitor sensitivity of MCT2
decreased relative to that of MCT2 associated with endogenous
basigin.Thisisnotwithoutprecedent,sincewehavedemonstrated
previously that inhibition of MCT1-mediated lactate transport by
the organomercurial reagent pCMBS (p-chloromercuribenzene
sulfonate) occurs when MCT1 associates with basigin, but
Figure 7 Schematic diagram of how MCT–ancillary protein interactions
may affect expression and AR-C155858 binding
Interactions between the TM of the ancillary protein and TMs 3 and 6 of the MCT are shown
as being either strong (thick arrows) or weak (broken arrows), whereas interactions between
the two C-terminal tails are shown as either moderate (thin arrow) or weak (broken arrows).
Inhibition by AR-C155858 is indicated by an arrow directing the inhibitor into its binding site.
The loss of this inhibition is indicated by an occlusion of the AR-C155858-binding site.
not embigin [22]. Unlike pCMBS, AR-C155858 binds to an
intracellular site on the MCT [38] and thus the insensitivity of
MCT2/embigin to inhibition by AR-C155858 is likely to involve
an effect of the embigin on either the access to or shape of the
intracellular inhibitor-binding domain. The former could involve
the intracellular tail of embigin interacting with the intracellular
face of MCT2 in a manner that is not possible with MCT1.
The latter could indicate that the interaction of the TM domain
of embigin, but not basigin, with TMs 3 and 6 of MCT1 and
MCT2 causes a subtle change in the shape of the intracellular
binding pocket of the MCT sufﬁcient to prevent inhibitor binding
in MCT2, but not MCT1. Such an effect might also account for
the lower kcat of MCT1 in rat erythrocytes, where it associates
with embigin, compared with MCT1 in rabbit erythrocytes,
where basigin is the ancillary protein. Interestingly, the binding
afﬁnity of AR-C155858 to MCT1 and MCT2 expressed in yeast,
where there is no basigin or embigin, is also different, with Kd
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values of 4.9 and 100 nM respectively [38]. Thus it is possible
that association of MCT2 with basigin enhances AR-C155858
binding, whereas association with embigin has either no effect or
reducesbindingafﬁnity.NosucheffectsareapparentwithMCT1.
Conclusions
In order to reconcile all of the results of the present study, we
propose the scheme shown in Figure 7. The key features of this
proposal are as follows.
(i) MCT2 binds preferentially to embigin over endogenous
basigin, with the binding to the latter requiring an interaction
between the C-termini of both proteins that is not required by
MCT1. Thus MCT1trn, but not MCT2trn, expresses well in the
absence of co-expressed embigin.
(ii) MCT1 associates with embigin in the absence of basigin,
but prefers the latter as binding partner when both are present,
unlesstheC-terminaltailofMCT2replacestheMCT1C-terminus
(MCT1/2c) when binding to embigin is promoted.
(iii) When bound to embigin, the binding afﬁnity of AR-
C155858 to MCT2, but not MCT1, is greatly reduced and this
effect is independent of the presence of the C-terminal tail of
MCT2.
Our data emphasize that the potency with which AR-C155858
inhibits MCT2 is dependent on the ancillary protein with which
it associates. In mammalian cells, embigin is the preferred
endogenous binding partner of MCT2 [22] and thus MCT2-
mediated lactate transport is likely to be considerably less
sensitive to inhibition by AR-C155858 than that mediated by
MCT1. This may justify the cautious use of AR-C155858 to
dissect out the different roles of MCT1 (very sensitive to AR-
C155858), MCT2 (less sensitive to AR-C155858) and MCT4
(insensitive to AR-C155858) in the metabolism of tissues such
as the brain, as has been reported by Br¨ oer and colleagues [41].
However,thedevelopmentoftotallyisoform-speciﬁcinhibitorsof
MCTs that are not inﬂuenced by the associated ancillary protein
is clearly desirable.
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Figure S1 Immunoﬂuorescent confocal microscopy of Xenopus oocyte sections expressing the various MCT constructs in the presence and absence of
exogenous embigin
Ab, antibody; 2◦, secondary.
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Table S1 Primers used in PCR generation of chimaeric MCTs and for detecting X. laevis basigin and embigin expression
Construct Forward primer (5 →3 ) Reverse primer (5 →3 )
MCT1/2 MCT1 fragment TCTTGGAATTCATCGACACCT CAAAAAGCCTCTATGGGTAA
MCT2 fragment TTTACCCATAGAGGCTTTTTG TGATTCGGAGATGAGACTT
MCT2/1 MCT1 fragment TTTACCCATAGAGGCTTTTTG ACACAAATGTCCACTGTCT
MCT2 fragment TCCAGAATTCGCTCAGAAATGCCATCAGAG CAAAAAGCCTCTATGGGTAA
MCT1/2c MCT1 fragment TCTTGGAATTCATCGACACCT AAGTCGATAATTGATGCCC
MCT2 fragment ATCAATTATCGACTTCTCGAGAAGG TGATTCGGAGATGAGACTT
MCT2/1c MCT1 fragment ATCAATTATCGACTTGTGGCC ACACAAATGTCCACTGTCT
MCT2 fragment TCCAGAATTCGCTCAGAAATGCCATCAGAG AAGTCGATAATTGATAGCATTGC
HA–MCT2trn MCT2trn from pGHJ CAACTGGGCCCGATCAATTCCCG CCATTCGGGTGTTCTTGAGGCTGG
MCT2trn from HA-pcDNA3 CCCAATCTAGATAGCTTACCATGTACCC CGGCCCTCTAGAGAATTCACTAGTGA
Basigin Xenopus basigin GATCCAGATATTACAACAATG GCATTAGGAGAAACAATGTACC
Embigin Xenopus embigin GTGATAGTTCCAAGTACAACCCAATCG CAACACTACTGCTCTCCTCCGATTTTAGG
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